MX2009006230A - Agonistas sinteticos de receptores de tipo toll 9. - Google Patents
Agonistas sinteticos de receptores de tipo toll 9.Info
- Publication number
- MX2009006230A MX2009006230A MX2009006230A MX2009006230A MX2009006230A MX 2009006230 A MX2009006230 A MX 2009006230A MX 2009006230 A MX2009006230 A MX 2009006230A MX 2009006230 A MX2009006230 A MX 2009006230A MX 2009006230 A MX2009006230 A MX 2009006230A
- Authority
- MX
- Mexico
- Prior art keywords
- tlr9
- agonists
- immune response
- synthetic agonists
- profiles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86960406P | 2006-12-12 | 2006-12-12 | |
| PCT/US2007/087182 WO2008073959A2 (en) | 2006-12-12 | 2007-12-12 | Synthetic agonists of tlr9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006230A true MX2009006230A (es) | 2009-06-22 |
Family
ID=39512457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006230A MX2009006230A (es) | 2006-12-12 | 2007-12-12 | Agonistas sinteticos de receptores de tipo toll 9. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7884197B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2079305A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010512421A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101610671A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007333146A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2671883A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006230A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008073959A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
| US20060074040A1 (en) * | 2003-07-15 | 2006-04-06 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| AU2014203624B2 (en) * | 2007-08-01 | 2016-05-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of TLR9 |
| WO2009018431A2 (en) * | 2007-08-01 | 2009-02-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| WO2010088395A2 (en) * | 2009-01-30 | 2010-08-05 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
| BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
| HUE026201T2 (en) | 2009-12-10 | 2016-05-30 | Hoffmann La Roche | Antibodies binding to human CSF1R extracellular domain 4 and their use |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| ES2626488T3 (es) | 2011-07-19 | 2017-07-25 | Wave Life Sciences Pte. Ltd. | Procedimientos para la síntesis de ácidos nucleicos funcionalizados |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
| ES2940887T3 (es) | 2012-07-13 | 2023-05-12 | Wave Life Sciences Ltd | Método de preparación de oligonucleótidos quirales |
| WO2014110081A1 (en) * | 2013-01-08 | 2014-07-17 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108048A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) * | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| JP6991857B2 (ja) * | 2014-10-10 | 2022-01-13 | イデラ ファーマシューティカルズ インコーポレイテッド | Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療 |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| EP3385383B1 (en) | 2015-12-04 | 2021-04-07 | Zenyaku Kogyo Co., Ltd. | Anti-il-17 aptamer having improved retention in blood |
| EP3484908A4 (en) | 2016-07-15 | 2020-04-08 | AM Chemicals Llc | NON-NUCLEOSIDIC SOLID CARRIERS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTID SYNTHESIS |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| CA3036978A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| JP7304287B2 (ja) | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| CN108728444A (zh) | 2017-04-18 | 2018-11-02 | 长春华普生物技术股份有限公司 | 免疫调节性多核苷酸及其应用 |
| US12460208B2 (en) | 2017-04-18 | 2025-11-04 | Parr Biotechnology Co., Ltd. | Immunomodulatory polynucleotides and uses thereof |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
| MY198034A (en) | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| US20230226050A1 (en) | 2020-07-02 | 2023-07-20 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
-
2007
- 2007-12-12 CN CNA200780051260XA patent/CN101610671A/zh active Pending
- 2007-12-12 EP EP07865548A patent/EP2079305A4/en not_active Withdrawn
- 2007-12-12 AU AU2007333146A patent/AU2007333146A1/en not_active Abandoned
- 2007-12-12 JP JP2009541545A patent/JP2010512421A/ja not_active Withdrawn
- 2007-12-12 MX MX2009006230A patent/MX2009006230A/es not_active Application Discontinuation
- 2007-12-12 CA CA002671883A patent/CA2671883A1/en not_active Abandoned
- 2007-12-12 WO PCT/US2007/087182 patent/WO2008073959A2/en not_active Ceased
- 2007-12-12 US US11/954,726 patent/US7884197B2/en not_active Expired - Fee Related
-
2010
- 2010-12-03 US US12/960,030 patent/US20110135669A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008073959A3 (en) | 2008-11-13 |
| WO2008073959A2 (en) | 2008-06-19 |
| CA2671883A1 (en) | 2008-06-19 |
| AU2007333146A1 (en) | 2008-06-19 |
| US20110135669A1 (en) | 2011-06-09 |
| US7884197B2 (en) | 2011-02-08 |
| US20080292648A1 (en) | 2008-11-27 |
| EP2079305A2 (en) | 2009-07-22 |
| CN101610671A (zh) | 2009-12-23 |
| EP2079305A4 (en) | 2010-01-27 |
| JP2010512421A (ja) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006230A (es) | Agonistas sinteticos de receptores de tipo toll 9. | |
| MX354267B (es) | Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos. | |
| MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
| MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
| MY161435A (en) | Anti-vegf antibodies and polynucleotides encoding the same | |
| MX2009005829A (es) | Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante. | |
| MX2014011837A (es) | Composiciones de aerogel precursor de geopolimero. | |
| WO2014028429A3 (en) | Enzymes and polymerases for the synthesis of rna | |
| IN2012DN00913A (cg-RX-API-DMAC7.html) | ||
| MX2011011925A (es) | Anticuerpos triespecificos o tetraespecificos. | |
| EP4219516A3 (en) | Chiral control | |
| MX344972B (es) | Oligonucleotidos inmunoestimulantes. | |
| IN2014CN02574A (cg-RX-API-DMAC7.html) | ||
| MX2012007710A (es) | Alfa-amilasas. | |
| IN2014DN09346A (cg-RX-API-DMAC7.html) | ||
| WO2015069847A3 (en) | Co-culture based modular engineering for the biosynthesis of isoprenoids, aromatics and aromatic-derived compounds | |
| WO2011160052A3 (en) | Methods and compositions for sequence specific rna endonucleases | |
| MY161868A (en) | Anti-bv8 antibodies and uses thereof | |
| IN2014CN04050A (cg-RX-API-DMAC7.html) | ||
| UA104875C2 (uk) | Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти) | |
| TN2013000201A1 (en) | Methods and compositions for drying coal | |
| NZ613887A (en) | Antimicrobial activity enhancing agent | |
| UA36194U (en) | Use of quercetin as hepatoprotector | |
| UA97521C2 (ru) | и-РНК-АГЕНТ, КОТОРЫЙ ОПОСРЕДУЕТ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC | |
| UA35660U (en) | Use of antihomotoxic preparations as cytoprotectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |